August 26, 2021 Erik AtkissonEiger BioPharmaceuticals, Inc. • November 4th, 2021 • Biological products, (no disgnostic substances)
SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • November 4th, 2021 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances)
THIS SIXTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of October 6, 2021, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise party thereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and EIGER BIOPHARMACEUTICALS, INC., a Delaware corporation (“Parent”), EB Pharma, LLC, a Delaware limited liability company (“EB Pharma”) and EBPI Merger, Inc., a Delaware corporation (“EBPI”), each with offices located at 2155 Park Blvd., Palo Alto, CA 94306 (Parent, EB Pharma and EBPI, individually and collectively, jointly and severally, “Borrower”).
